



Fact Sheet

MULTI-LINK VISION[®] Stent System

The MULTI-LINK VISION[®] Coronary Stent System is the first and only cobalt chromium stent for the treatment of coronary artery disease. Cobalt chromium is stronger and more radiopaque (more visible under fluoroscopy) than stainless steel, so a cobalt chromium stent can have thinner struts, yet still maintains similar strength and visibility as thicker strutted, conventional stainless steel stents.

The MULTI-LINK VISION stent has the thinnest struts available on the U.S. market – .0032" thick. Thinner struts make the MULTI-LINK VISION stent extremely deliverable, and clinical research has shown that thinner struts are linked to lower restenosis rates, less vessel injury and improved outcomes.

Based on a large body of clinical data, the MULTI-LINK VISION stent exhibits enhanced performance, including a six-month clinically driven Target Lesion Revascularization (TLR) of 1.9 percent.

Use in XIENCE[™] V Everolimus Eluting Coronary Stent System

There are four primary components of a drug eluting stent: the stent and stent delivery system; the drug that “elutes,” or is released from the stent, and the polymer coating, which controls the release of the drug into the coronary artery. The MULTI-LINK VISION coronary stent and the MULTI-LINK VISION stent delivery system are used in Abbott Vascular’s next-generation drug eluting stent – the XIENCE[™] V Everolimus Eluting Coronary Stent System. XIENCE V has received a CE Mark in Europe and is currently an investigational device within the United States and Japan.

About the MULTI-LINK VISION Stent System

The MULTI-LINK VISION Stent System was launched in Europe in December 2002 and in the United States in July 2003 by Guidant Corporation, the predominant U.S. market leader in metallic stents since the introduction of the company’s first stent system in 1997. In April 2006, Abbott acquired the vascular intervention and endovascular solutions businesses of Guidant.

###

LT2922560G